CME Group (CME) transformation chief sells 5,160 Class A shares

Rhea-AI Filing Summary

CME Group Inc. Chief Transformation Officer Ken Vroman reported an open-market sale of Class A common stock. On March 12, 2026, he sold 5,160 shares at a weighted average price of $309.00 per share, with individual trade prices ranging from $308.969 to $309.11. Following this transaction, he directly holds 14,910 CME Group Class A common shares.

Insider Trade Summary

Net Seller: 5,160 shares ($1,594,440)

Net Sell 1 txn

Insider Vroman Ken

Role Chief Transformation Officer

Sold 5,160 shs ($1.59M)

Type	Security	Shares	Price	Value
Sale	Common Stock Class A	5,160	$309.00	$1.59M

Holdings After Transaction: Common Stock Class A — 14,910 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vroman Ken

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Transformation Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	03/12/2026		S		5,160	D	$309(1)	14,910	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 12, 2026, Mr. Vroman sold an aggregate of 5160 shares of CME Group Class A common stock. For reporting purposes, the sale prices within $1 range have been aggregated and the weighted average has been reported. The price range was $308.969 to $309.11. The Company maintains a record of the transaction and copies will be provided upon request.

Remarks:

	By: Margaret Austin Wright For: Kendal L. Vroman	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CME (CME) report for Ken Vroman?

CME Group reported that Chief Transformation Officer Ken Vroman executed an open-market sale of Class A common stock. On March 12, 2026, he sold 5,160 shares as part of a single aggregated transaction reported in this Form 4 filing.

How many CME Group shares did Ken Vroman sell and at what price?

Ken Vroman sold 5,160 shares of CME Group Class A common stock. The weighted average sale price reported was $309.00 per share, reflecting multiple trades within a narrow price band over that trading day.

What price range applied to Ken Vroman’s CME share sale?

The reported sale prices for Ken Vroman’s transaction ranged from $308.969 to $309.11 per share. These individual trades were aggregated for reporting, and the weighted average price of $309.00 per share was disclosed in the Form 4 footnote.

How many CME Group shares does Ken Vroman hold after this sale?

After completing the reported sale, Ken Vroman directly holds 14,910 shares of CME Group Class A common stock. This post-transaction ownership figure is disclosed in the Form 4 as the total shares beneficially owned following the sale.

What type of security did Ken Vroman trade in this CME filing?

Ken Vroman traded non-derivative equity in the form of CME Group Class A common stock. The Form 4 identifies the security title as “Common Stock Class A,” indicating a straightforward share sale rather than an option or other derivative exercise.

Was Ken Vroman’s CME transaction an open-market sale or another type?

The filing describes Ken Vroman’s transaction as an open-market sale of common stock. The Form 4 uses transaction code “S,” defined as a sale in the open market or a private transaction, confirming it was a standard disposition of shares.